Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Clinical trial NCT04895761 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04895761
- Sponsor
- Providence Health & Services
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-10
- Primary completion
- 2023-06-16
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.